Wir sind mit live! Mehr erfahren

Revvity

RVTY

Börsenwert 17 Mrd. $

152,64 USD

-2,07

1,34 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

152,64

0,00

0 %

1 Tag

-1,34 %

5 Tage

-0,72 %

1 Monat

4,74 %

3 Monate

36,65 %

6 Monate

70,49 %

Seit Jahresbeginn

55,52 %

1 Jahr

62,38 %

5 Jahre

-10,42 %

10 Jahre

194,61 %

Profil: Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.

Mitarbeiter: 11.000

Gesundheitswesen Diagnostik & Research

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 40 %

Neutral 60 %

Negativ 0 %

How to Invest in AI Drug Discovery

.Danaher (DHR), one of the world's largest providers of medical diagnostics and laboratory equipment, recently announced plans to launch its first AI-powered autonomous laboratory, scheduled to operate at commercial scale in early 2027. While market trading barely moved the stock on the announcement date, the news marks a quiet turning point for life science automation.

How to Invest in AI Drug Discovery

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: 2026 Jefferies Global Healthcare Conference Tuesday, November 17, 2026 8:00 a.m. GMT – Prahlad Singh, president and chief executive officer 9th Annual Evercore Healthcare Conference Wednesday, December 2, 2026 9:10 a.m. ET – Prahlad Singh Attendees will receive an update on the Company and its strategic priorities during fireside chats. Live audio webcasts will be.

Revvity to Present at Upcoming Investor Conferences

Revvity to Host Investor Day

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will host its 2026 Investor Day on Friday, November 13 at 9:00 a.m. ET.Presentations from members of Revvity's senior management team will provide updates on the Company's key business initiatives, operational achievements and financial outlook.To register for the Investor Day webcast, visit here. A replay of the webcast and all presentations will be available on the Events page of the Revvity Investor Relations webs.

Revvity to Host Investor Day

Zacks Investment Research

Revvity (RVTY) Upgraded to Buy: What Does It Mean for the Stock?

Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Revvity (RVTY) Upgraded to Buy: What Does It Mean for the Stock?

Revvity to Hold Earnings Call on November 3, 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2026 financial results prior to market open on Tuesday, November 3, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section o.

Revvity to Hold Earnings Call on November 3, 2026

Zacks Investment Research

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

RVTY's diagnostics growth, AI-driven demand and life sciences expansion support its outlook, though China and margin pressures pose near-term challenges.

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

Zacks Investment Research

RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection

Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.

RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection

Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population-wide screening programs that identify children at risk of developing type 1 diabetes (T1D) before symptoms appear. A critical public health challenge, T1D is often only identified after significant beta-cell damage has occurred, presenting first as a life-threatening diabetic k.

Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes

Zacks Investment Research

Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?

Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?

Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript

Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript

Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt